Despite the recent progress in the field of causal inference, to date there is no agreed upon methodology to glean treatment effect estimation from observational data. The consequence on clinical practice is that, when lacking results from a randomized trial, medical personnel is left without guidance on what seems to be effective in a real-world scenario. This article showcases a pragmatic methodology to obtain preliminary estimation of treatment effect from observational studies. Our approach was tested on the estimation of treatment effect of the proning maneuver on oxygenation levels, on a cohort of COVID-19 Intensive Care patients. We modeled our study design on a recent RCT for proning (the PROSEVA trial). Linear regression, propensity score models such as blocking and DR-IPW, BART and two versions of Counterfactual Regression were employed to provide estimates on observational data comprising first wave COVID-19 ICU patient data from 25 Dutch hospitals. 6371 data points, from 745 mechanically ventilated patients, were included in the study. Estimates for the early effect of proning -- P/F ratio from 2 to 8 hours after proning -- ranged between 14.54 and 20.11 mm Hg depending on the model. Estimates for the late effect of proning -- oxygenation from 12 to 24 hours after proning -- ranged between 13.53 and 15.26 mm Hg. All confidence interval being strictly above zero indicated that the effect of proning on oxygenation for COVID-19 patient was positive and comparable in magnitude to the effect on non COVID-19 patients. These results provide further evidence on the effectiveness of proning on the treatment of COVID-19 patients. This study, along with the accompanying open-source code, provides a blueprint for treatment effect estimation in scenarios where RCT data is lacking. Funding: SIDN fund, CovidPredict consortium, Pacmed.

Modeling a system's temporal behaviour in reaction to external stimuli is a fundamental problem in many areas. Pure Machine Learning (ML) approaches often fail in the small sample regime and cannot provide actionable insights beyond predictions. A promising modification has been to incorporate expert domain knowledge into ML models. The application we consider is predicting the progression of disease under medications, where a plethora of domain knowledge is available from pharmacology. Pharmacological models describe the dynamics of carefully-chosen medically meaningful variables in terms of systems of Ordinary Differential Equations (ODEs). However, these models only describe a limited collection of variables, and these variables are often not observable in clinical environments. To close this gap, we propose the latent hybridisation model (LHM) that integrates a system of expert-designed ODEs with machine-learned Neural ODEs to fully describe the dynamics of the system and to link the expert and latent variables to observable quantities. We evaluated LHM on synthetic data as well as real-world intensive care data of COVID-19 patients. LHM consistently outperforms previous works, especially when few training samples are available such as at the beginning of the pandemic.

The Multiple Sclerosis Society of Canada has awarded CA$1 million to a project helping doctors who treat multiple sclerosis (MS) patients make more personalized treatment decisions through the use of artificial intelligence (AI). The society awarded the five-year grant (worth about $814,800) to Douglas Arnold, MD, a neurologist with Neuro (the Montreal Neurological Institute-Hospital) at McGill University, with expertise in using magnetic resonance imaging (MRI) to assess MS and Alzheimer's disease. "We are entering a new era in which'Big Data' and increasing computer power are making it possible to develop artificial intelligence methods capable of predicting how individual MS patients will do in the future and how they will respond to specific treatments," Arnold said in a press release. "Clinicians cannot make such predictions at present," he added. "Integrating AI into the clinic will allow clinicians to adapt treatments to each individual patient's unique circumstances, to help ensure a better outcome."